Fig. 4From: Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II studyOf the patients that were included in the FIN-GAR phase I registry, 100 responded in the phase II questionnaire and their data was updated. In addition, 29 new patients were included in the registry. In the FIN-GAR phase II registry the data of 132 patients was obtained from the FIN-GAR phase I registryBack to article page